Reviva Pharmaceuticals Holdings, Inc. Convertible Debt
Reviva Pharmaceuticals Holdings, Inc. (RVPH) had Convertible Debt of $75.00 thousand as of 2020-11-12, per its 10-Q filed 2021-01-14.
Discontinued › Balance Sheet › Liabilities
us-gaap:ConvertibleDebt · last filed 2021-01-14
- 2020-11-12: Convertible Debt $75.00K.
- 2020-09-24: Convertible Debt $75.00K.
| Period end | Convertible Debt |
|---|---|
| 2020-11-12 | $75.00K 10-Q · filed 2021-01-14 |
| 2020-09-24 | $75.00K 10-Q · filed 2021-01-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |